DS
CRSP icon

David Shaw’s CRISPR Therapeutics CRSP Stock Holding History

David Shaw’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.7M Buy
+893,812
New +$47.1M 0.02% 774
2024
Q4 		– Sell
-29,365
Closed -$1.39M – 4471
2024
Q3 		$1.38M Buy
29,365
+1,191
+4% +$60.4K ﹤0.01% 3014
2024
Q2 		$1.52M Sell
28,174
-146,121
-84% -$8.45M ﹤0.01% 2895
2024
Q1 		$11.9M Buy
174,295
+137,023
+368% +$9.81M 0.01% 1258
2023
Q4 		$2.33M Buy
+37,272
New +$2.06M ﹤0.01% 2545
2023
Q2 		– Sell
-4,600
Closed -$261K – 4286
2023
Q1 		$208K Sell
4,600
-9,300
-67% -$452K ﹤0.01% 3889
2022
Q4 		$565K Buy
+13,900
New +$737K ﹤0.01% 3789
2022
Q2 		– Sell
-37,620
Closed -$2.21M – 5397
2022
Q1 		$2.36M Buy
37,620
+14,448
+62% +$907K ﹤0.01% 3150
2021
Q4 		$1.76M Sell
23,172
-11,524
-33% -$1.01M ﹤0.01% 3470
2021
Q3 		$3.88M Buy
34,696
+9,798
+39% +$1.23M ﹤0.01% 2365
2021
Q2 		$4.03M Sell
24,898
-52,294
-68% -$6.36M ﹤0.01% 2235
2021
Q1 		$9.41M Sell
77,192
-205,959
-73% -$31.1M 0.01% 1401
2020
Q4 		$43.4M Buy
283,151
+16,284
+6% +$1.92M 0.04% 563
2020
Q3 		$22.3M Sell
266,867
-61,757
-19% -$5.48M 0.02% 774
2020
Q2 		$24.1M Buy
328,624
+52,765
+19% +$3.09M 0.03% 681
2020
Q1 		$11.7M Buy
275,859
+267,192
+3,083% +$13.8M 0.02% 907
2019
Q4 		$528K Sell
8,667
-11,417
-57% -$623K ﹤0.01% 3366
2019
Q3 		$823K Buy
20,084
+13,065
+186% +$624K ﹤0.01% 2926
2019
Q2 		$331K Buy
7,019
+467
+7% +$18.7K ﹤0.01% 3273
2019
Q1 		$234K Sell
6,552
-18,160
-73% -$628K ﹤0.01% 3335
2018
Q4 		$706K Buy
24,712
+19,177
+346% +$667K ﹤0.01% 2890
2018
Q3 		$245K Sell
5,535
-152
-3% -$7.96K ﹤0.01% 3448
2018
Q2 		$334K Sell
5,687
-10,308
-64% -$587K ﹤0.01% 3324
2018
Q1 		$731K Buy
+15,995
New +$660K ﹤0.01% 2697

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's CRSP Position: Q2 2026 in Review

David Shaw opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 893,812 shares worth $48.7M. The stake represents 0.02% of the portfolio and ranks #774 among its holdings. This is a return to the name: David Shaw previously reported a position in CRSP as recently as Q3 2024.

David Shaw first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • David Shaw held 893,812 shares of CRISPR Therapeutics worth $48.7M as of Q2 2026.
  • CRISPR Therapeutics was a new David Shaw position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of David Shaw's portfolio in Q2 2026, its #774 holding.
  • David Shaw first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.